[1] Yeo Y H, Lee Y T, Tseng H R, et al. Alpha-fetoprotein:past, present, and future[J]. Hepatol Commun, 2024, 8(5):e0422.
[2] Than N N, Ghazanfar A, Hodson J, et al. Comparing clinical presentations, treatments and outcomes of hepatocellular carcinoma due to hepatitis C and non-alcoholic fatty liver disease[J]. QJM, 2017, 110(2):73-81.
[3] Singal A G, Llovet J M, Yarchoan M, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma[J]. Hepatology, 2023, 78(6):1922-1965.
[4] Chen S, Li J, Tan X, et al. Clinical role of combining alpha-fetoprotein and lens culinaris agglutinin-reactive fraction of alpha-fetoprotein for hepatocellular carcinoma:evidence from literature and an original study[J]. J Clin Lab Anal, 2020, 34(7):e23262.
[5] Tzartzeva K, Obi J, Rich N E, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis:a meta-analysis[J]. Gastroenterology, 2018, 154(6):1706-1718.e1.
[6] Philips C A, Rajesh S, Nair D C, et al. Hepatocellular carcinoma in 2021:an exhaustive update[J]. Cureus, 2021, 13(11):e19274.
[7] Singal A G, Haaland B, Parikh N D, et al. Comparison of a multitarget blood test to ultrasound and alpha-fetoprotein for hepatocellular carcinoma surveillance:results of a network meta-analysis[J]. Hepatol Commun, 2022, 6(10):2925-2936.
[8] Lee Y T, Wang J J, Luu M, et al. The mortality and overall survival trends of primary liver cancer in the United States[J]. J Natl Cancer Inst, 2021, 113(11):1531-1541.
[9] Tayob N, Kanwal F, Alsarraj A, et al. The performance of AFP, AFP-3, DCP as biomarkers for detection of hepatocellular carcinoma (HCC):a phase 3 biomarker study in the United States[J]. Clin Gastroenterol Hepatol, 2023, 21(2):415-423.e4.
[10] Kim N J, Li M, Vutien P, et al, Changes in liver disease etiology support a lower alpha-fetoprotein threshold for hepatocellular carcinoma screening[J]. Gastroenterology, 2026, 170(3):606-618.
[11] Rui H, Yueqin N, Wei W, et al. Combining AFP, PIVKA-II, and GP73 has diagnostic utility for hepatitis B-associated hepatocellular carcinoma and is consistent with liver pathology results[J]. Sci Rep, 2025, 15(1):14869.
[12] Singal A G, Chhatwal J, Parikh N, et al. Cost-effectiveness of a biomarker-based screening strategy for hepatocellular carcinoma in patients with cirrhosis[J]. Liver Cancer, 2024, 13(6):643-654.
[13] Song H C, Gwak H S. Differential diagnosis of a well-enhancing intracisternal lesion in a breast cancer patient[J]. Brain Tumor Res Treat, 2025, 13(1):34-38.
[14] Narasimman M, Hernaez R, Cerda V, et al. Hepatocellular carcinoma surveillance may be associated with potential psychological harms in patients with cirrhosis[J]. Hepatology, 2024, 79(1):107-117.
[15] Zhang J, Chen G, Zhang P, et al. The threshold of alpha-fetoprotein (AFP) for the diagnosis of hepatocellular carcinoma:a systematic review and meta-analysis[J]. PLoS One, 2020, 15(2):e0228857.
[16] Beudeker B J B, Fu S, Balderramo D, et al. Validation and optimization of AFP-based biomarker panels for early HCC detection in Latin America and Europe[J]. Hepatol Commun, 2023, 7(10).e0264.
[17] Rutili de Lima C, Khan S G, Shah S H, et al. Mask region-based CNNs for cervical cancer progression diagnosis on pap smear examinations[J]. Heliyon, 2023, 9(11):e21388.
[18] Li K, Mathew B, Saldanha E, et al. New insights into biomarkers and risk stratification to predict hepatocellular cancer[J]. Mol Med, 2025, 31(1):152.
[19] Piratvisuth T, Hou J, Tanwandee T, et al. Development and clinical validation of a novel algorithmic score (GAAD) for detecting HCC in prospective cohort studies[J]. Hepatol Commun, 2023, 7(11),e0317.
[20] Parikh N D, Tayob N, Singal A G. Blood-based biomarkers for hepatocellular carcinoma screening:approaching the end of the ultrasound era?[J].J Hepatol, 2023, 78(1):207-216.
[21] Jaber F, El-Serag H B. HES V2.0 surpasses GALAD for HCC detection:a review of multi-dimensional biomarker scores and studies[J]. Hepat Oncol, 2025, 12(1):2494446. |
